44 Result(s)

Article

Defining the critical hurdles in cancer immunotherapy

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a ...

Bernard A Fox, Dolores J Schendel, Lisa H Butterfield… in Journal of Translational Medicine (2011)

Article

NF-κB as potential target in the treatment of melanoma

The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors h...

Gabriele Madonna, Claudio Dansky Ullman… in Journal of Translational Medicine (2012)

Article

Tumor biobanks in translational medicine

The concept of tissue banking as a “bio-repository” aimed to collection, storing and distribution of human biological material and clinical information, is emerging as a successful strategy to support clinical...

Gerardo Botti, Renato Franco, Monica Cantile… in Journal of Translational Medicine (2012)

Article

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 facto...

Antonio Daponte, Simona Signoriello, Luigi Maiorino… in Journal of Translational Medicine (2013)

Article

Do BRAF inhibitors select for populations with different disease progression kinetics?

Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experie...

Paolo Antonio Ascierto, Ester Simeone… in Journal of Translational Medicine (2013)

Article

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4⁺CD25⁺⁺Foxp3⁺ regulatory T-cells in advanced melanoma patients

In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example, a ...

Laura Ridolfi, Massimiliano Petrini… in Journal of Translational Medicine (2013)

Article

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies

Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified to be r...

Luigi Fattore, Emanuele Marra, Maria Elena Pisanu… in Journal of Translational Medicine (2013)

Article

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was th...

Maresa Altomonte, Anna Maria Di Giacomo… in Journal of Experimental & Clinical Cancer … (2013)

Article

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis

Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electroche...

Corrado Caracò, Nicola Mozzillo, Ugo Marone, Ester Simeone, Lucia Benedetto… in BMC Cancer (2013)

Article

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes (EAPs) suggest ipilimumab...

Vanna Chiarion Sileni, Jacopo Pigozzo… in Journal of Experimental & Clinical Cancer … (2014)

Article

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

Maurizio Montella, Sara Gandini, Carlo Riccardo Rossi… in Journal of Translational Medicine (2014)

Article

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition

Luigi Fattore, Emanuele Marra, Maria Elena Pisanu… in Journal of Translational Medicine (2014)

Article

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma

Maria Colombino, Maria Cristina Sini, Amelia Lissia… in Journal of Translational Medicine (2014)

Article

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma

Nicola Mozzillo, Corrado Caracò, Ugo Marone… in Journal of Translational Medicine (2014)

Article

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit tumor growth, suggesting a potential role in melanoma treatment.

Emilia Caputo, Roberta Miceli, Maria Letizia Motti… in Journal of Translational Medicine (2014)

Article

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors

Luigi Fattore, Debora Malpicci, Emanuele Marra… in Journal of Translational Medicine (2015)

Article

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Stefania Stucci, Marco Tucci, Paolo Antonio Ascierto… in Journal of Translational Medicine (2015)

Article

Melanoma and immunotherapy bridge 2015

MELANOMA BRIDGE 2015

Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu… in Journal of Translational Medicine (2016)